Scroll to explore

Immuno-oncology programs

GPCRs constitute strategic targets mediating immunosuppression. The company exploits its expertise in the field to move forward small molecule and antibody based-assets toward the clinic.


Merck is one of Domain Therapeutics’s partners

A2aR/A2bR antagonist (M1069)

Discover more

EP4 receptor antagonist (DT-9081)

Discover more

Anti-CCR8 antibody

Discover more

Undisclosed GPCR targets

Discover more